Mackenzie Financial
IOVA icon

Mackenzie Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Mackenzie Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,360
Closed -$45.2K – 1582
2025
Q4 		$45.2K Sell
16,360
-1,127
-6% -$2.61K ﹤0.01% 1621
2025
Q3 		$37.9K Hold
17,487
– – ﹤0.01% 1665
2025
Q2 		$30.1K Hold
17,487
– – ﹤0.01% 1663
2025
Q1 		$58.2K Hold
17,487
– – ﹤0.01% 1618
2024
Q4 		$129K Buy
17,487
+1,540
+10% +$14.3K ﹤0.01% 1613
2024
Q3 		$150K Buy
15,947
+1,784
+13% +$16.9K ﹤0.01% 1435
2024
Q2 		$114K Hold
14,163
– – ﹤0.01% 1418
2024
Q1 		$210K Buy
+14,163
New +$165K ﹤0.01% 1327
2023
Q2 		– Sell
-60,571
Closed -$370K – 1573
2023
Q1 		$370K Buy
+60,571
New +$418K ﹤0.01% 1112
2022
Q3 		– Sell
-10,325
Closed -$114K – 1483
2022
Q2 		$114K Buy
+10,325
New +$135K ﹤0.01% 1333

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Mackenzie Financial's IOVA Position: Q1 2026 in Review

Mackenzie Financial sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 16,360 shares — an estimated $45.2K sold.

Mackenzie Financial first reported a position in IOVA in Q2 2022 and held it in 10 quarters. The position peaked at $370K in Q1 2023. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Mackenzie Financial reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 16,360 Iovance Biotherapeutics shares in Q1 2026, an estimated $45.2K.
  • Mackenzie Financial first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 10 quarters.
  • Mackenzie Financial's Iovance Biotherapeutics position peaked at $370K in Q1 2023.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.